DDInter1818 DDInter899
Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Tirofiban {u} (Compound) treats {v} (Disease) coronary artery disease
Tirofiban {u} (Compound) binds {v} (Gene) ITGA2B
Tirofiban {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Platelet Aggregation
Tirofiban {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Tirofiban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Tirofiban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Iloprost
Tirofiban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Icosapent
Tirofiban {u} may lead to a major life threatening interaction when taken with {v} Anistreplase
Tirofiban {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Tirofiban (Compound) treats coronary artery disease (Disease)
Tirofiban (Compound) binds ITGA2B (Gene)
Tirofiban (Compound) is included by Decreased Platelet Aggregation (Pharmacologic Class)
Tirofiban (Compound) causes Hypersensitivity (Side Effect)
Tirofiban may cause a minor interaction that can limit clinical effects when taken with Capsicum
Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Icosapent
Tirofiban may lead to a major life threatening interaction when taken with Anistreplase
Tirofiban may lead to a major life threatening interaction when taken with Dasatinib